FDA COVID-19 news roundup this week

By Jenni Spinner contact

- Last updated on GMT

(12963734/iStock via Getty Images Plus)
(12963734/iStock via Getty Images Plus)

Related tags: Fda, COVID-19, Coronavirus, Regulation, Testing

The federal agency has offered updates, advice and action regarding the COVID-19 pandemic, helping life-sciences professionals stay on top of developments.

While pharma firms and their partners continue to work diligently on vaccines and treatments for  COVID-19, the US Food and Drug Administration (FDA) continues to serve as a resource, providing information and guidance.

Convalescent plasma

The FDA updated its guidance regarding investigational COVID-19 convalescent plasma. The updated guidance extends the period of enforcement discretion through the end of February 2021.

This extension will allow continued access to convalescent plasma for the treatment of hospitalized COVID-19 patients while blood establishments develop the necessary operating procedures to manufacture the plasma consistent with the emergency use authorization (EUA). The guidance also includes a new recommendation that authorized COVID-19 convalescent plasma not be collected from individuals who have received an investigational COVID-19 vaccine.

Treatment development update

The agency updated the dashboard on its Coronavirus Treatment Acceleration Program (CTAP) webpage. The resource is intended to provide  current information about the agency’s special emergency program to help develop treatments for COVID-19.

As of October 31, more than 560 drug development programs stood in planning stages, more than 370 clinical trials had been reviewed by the FDA, five COVID-19 treatments were authorized for emergency use, and one treatment was approved by FDA for treatment of COVID-19.

Fradulent products

Many manufactures of consumer products have received warning letters for making and selling items purported to prevent, treat or cure COVID-19; to date, the FDA has not authorized or approved any such products to deal with the virus. The agency recently took more severe action at a flagrant violator of the rules.

The US Department of Justice (at the request of the FDA) filed a civil complaint in the US District Court for the District of New Jersey against Natural Solutions Foundation and two individuals associated with the entity. The complaint is directed at Rima Laibow and Ralph Fucetola, seeking to permanently enjoin them from distributing Dr. Rima Recommends Nano Silver 10PPM in interstate commerce as a prevention or treatment for COVID-19 and other diseases.

The next possible step, if the defendants are found to be in continued violation, would be to go to trial. At that point, the government could pursue a permanent injunction against them.

Related news

Show more

Related products

show more

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more